Clinical trials: HIV Seropositivity
HIV Antibody Positivity
Feasibility of Positive Links for Youth Care Engagement Intervention
A small pilot study to assess feasibility and acceptability of the PL4Y intervention.
- Trial name
- NCT05689515
- Testing
- Mobile health app
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus…
- Conditions
- Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive
- Trial name
- NCT03603808
- Testing
- Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 44 people
- Sponsor
- AIDS Malignancy Consortium
HIV Seropositivity, Bisexuality
Telehealth Delivery (Tele-B6)
The research team has developed an interventional group program for young men living with HIV and will be adapting it for telehealth delivery.
- Trial name
- NCT05829759
- Testing
- Tele-B6, Delayed intervention (waitlist control)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Methamphetamine Abuse, Opioid-use Disorder
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
The investigators propose to develop and evaluate optimal combinations of evidence-based interventions to improve HIV outcomes and reduce methamphetamine use (hereafter: meth use) among people with opioid use disorder who are in…
- Conditions
- Methamphetamine Abuse, Opioid-use Disorder, HIV Seropositivity
- Trial name
- STAR-OM (NCT04706624)
- Testing
- Contingency management (12 weeks), Contingency management (6 weeks), SMS reminders
- Where
- 4 sites in Vietnam
- Volunteers
- 667 people
- Sponsor
- Hanoi Medical University
HIV Positive, Ageing
The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'
The purpose of this study is to identify medical conditions that may cause particular problems to individuals receiving care for HIV infection over the age of 50.
- Trial name
- POPPY (NCT01737047)
- Where
- 8 sites in Ireland, United Kingdom
- Volunteers
- 1,377 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Human Immunodeficiency Virus, HIV Seropositivity
iTransition Development
Youth living with HIV are at high risk of falling out of care when they transition from pediatric to adult care. The investigators are proposing to develop a mobile app to help both clinical providers and patients navigate this…
- Trial name
- NCT04383223
- Testing
- iTransition
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- Emory University
HIV Infections, Renal Transplant Rejection
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant
This is an open-label study, where participants will be switched from their current HIV medication to the study drug, BIC/F/TAF. Open-label means both the investigator and the participant will know what drug will be given.
- Trial name
- NCT04530630
- Testing
- BIC/F/TAF 50Mg-200Mg-25Mg Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
HIV Infections, HIV-1-infection
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of Lamivudine (150 mg BID) plus Raltegravir (400 mg BID) switching to Lamivudine (300 mg QD)…
- Conditions
- HIV Infections, HIV-1-infection, HIV Seropositivity
- Trial name
- NCT03311945
- Testing
- Raltegravir, Lamivudine
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- Judit Pich
HIV Seroconversion, Stimulant Abuse
Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men
This study seeks to evaluate the efficacy of a contingency management (CM) intervention compared to a yoked control condition for eliminating illicit stimulant use and for decreasing time to initiating post exposure prophylaxis…
- Trial name
- NCT01140880
- Testing
- Truvada
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Friends Research Institute, Inc.
HIV Positive
Oligonucleotide Ligation Assay (OLA) Resistance Study
The investigators propose to gauge improvements in the rate of durable suppression of viral replication by ART when OLA is used to guide clinical decisions at the PEPFAR Coptic Hope Center in Kenya, and to determine the…
- Trial name
- OLA (NCT01898754)
- Testing
- Pre-ART Oligonucleotide Assay (OLA)
- Where
- 2 sites in Kenya
- Volunteers
- 991 people
- Sponsor
- University of Washington
HIV Positive, Alcohol Use
Alcohol Research Consortium in HIV-Intervention Research Arm
Aim 1: Examine effects of algorithm-guided alcohol treatment on alcohol consumption and alcohol use Disorders (AUD) symptoms. Aim 2: Examine effects of algorithm-guided alcohol treatment on retention in HIV care and HIV-related…
- Trial name
- ARCH-IRA (NCT02938377)
- Testing
- Computerized Brief Intervention (CBI), CBT4CBT, Recommendation and Counseling for Alcohol Pharmacotherapy
- Where
- 2 sites in United States
- Volunteers
- 4,985 people
- Sponsor
- University of Alabama at Birmingham
Household Contacts
A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.
This study will include male and female participants who live or work in the same household as a patient in one of the fordadistrogene movaparvovec interventional studies.
- Trial name
- NCT04543357
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
End Stage Kidney Disease
Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
Patients on haemodialysis are at higher risk of getting a severe form of COVID-19 if they become infected. Vaccinations are soon to arrive and offer great hope of controlling the current pandemic.
- Trial name
- NCT04815850
- Where
- United Kingdom
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Kaposi's Sarcoma, HIV Positive
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.
- Conditions
- Kaposi's Sarcoma, HIV Positive, AIDS
- Trial name
- NCT02029430
- Testing
- 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- ImmunityBio, Inc.
HIV Infections, ART
Evaluation of Secondary Distribution of HIV Self-screening Tests by Women With HIV
Many South African men do not visit clinics or get tested due to multiple real and perceived barriers. Nkangala District has significant gaps to identifying PLHIV who are not on ART, reaching their ART targets, especially in…
- Conditions
- HIV Infections, ART, HIV Seropositivity
- Trial name
- HIVSSSA (NCT05074251)
- Testing
- HIV self test, Counseling and referral for partner testing
- Where
- South Africa
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV Seropositivity
Early Community Client-LED ART Delivery in Nakivale Refugee Settlement
To pilot early community client-led ART (anti-retroviral therapy) delivery (CCLAD) in Nakivale Refugee Settlement in Uganda and assess the feasibility and acceptability of this intervention in this setting.
- Trial name
- Early CCLAD (NCT04736316)
- Testing
- Early CCLAD
- Where
- Uganda
- Volunteers
- 92 people
- Sponsor
- University of Washington
Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Background: Burkitt lymphoma/leukemia (BL) is highly treatable, but most of the standard therapies require multiple doses of intensive chemotherapy that may require long hospital stays and frequently have severe side effects.
- Conditions
- Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
- Trial name
- NCT01092182
- Testing
- EPOCH-R, EPOCH-RR
- Where
- 30 sites in United States
- Volunteers
- 194 people
- Sponsor
- National Cancer Institute (NCI)
Human Immunodeficiency Virus (HIV) Positive
Positive Health Check Evaluation Trial
The purpose of the study is to evaluate the effect of Positive Health Check (PHC), an online intervention that delivers tailored, evidence-based prevention messages to HIV positive patients, on improving clinical outcomes and…
- Trial name
- (PHC) (NCT03292913)
- Testing
- Positive Health Check, Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 799 people
- Sponsor
- RTI International
HPV Seroconversion
Gardasil Immunogenicity With Needle-Free Injection
Using biospecimens collected in a trial by the Thai Red Cross AIDS Research Center that studied two new human papillomavirus (HPV) vaccine delivery regimens, the investigators at UCSF will be testing the serum for antibodies to…
- Trial name
- GINI (NCT01924754)
- Where
- 2 sites in United States, Thailand
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV Seropositivity, Metabolic Syndrome
Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
This study will provide data on the switch from a protease inhibitor or efavirenz to the new formulation of raltegravir (RAL) dosed once daily.
- Conditions
- HIV Seropositivity, Metabolic Syndrome, Fatty Liver
- Trial name
- OBERAL (NCT03374358)
- Testing
- Raltegravir
- Where
- Finland
- Volunteers
- 45 people
- Sponsor
- Helsinki University Central Hospital